TUDCA-treated chronic kidney disease-derived hMSCs improve therapeutic efficacy in ischemic disease via PrPC

MLA

Chul Won Yun, et al. “TUDCA-Treated Chronic Kidney Disease-Derived HMSCs Improve Therapeutic Efficacy in Ischemic Disease via PrPC.” Redox Biology, vol. 22, Apr. 2019, p. 101144. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....713ec85bed045ee994c40f027fba8c18&authtype=sso&custid=ns315887.

APA

Chul Won Yun, Hyunjin Noh, Sang Hun Lee, Yeo Min Yoon, SangMin Kim, Jun Hee Lee, & Yong-Seok Han. (2019). TUDCA-treated chronic kidney disease-derived hMSCs improve therapeutic efficacy in ischemic disease via PrPC. Redox Biology, 22, 101144.

Chicago

Chul Won Yun, Hyunjin Noh, Sang Hun Lee, Yeo Min Yoon, SangMin Kim, Jun Hee Lee, and Yong-Seok Han. 2019. “TUDCA-Treated Chronic Kidney Disease-Derived HMSCs Improve Therapeutic Efficacy in Ischemic Disease via PrPC.” Redox Biology 22 (April): 101144. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....713ec85bed045ee994c40f027fba8c18&authtype=sso&custid=ns315887.